Did Alpha Cognition beat or miss consensus estimates last quarter?

What guidance did Alpha Cognition's management provide for the next earnings period?

What factors drove the changes in Alpha Cognition's revenue and profit?

What were the key takeaways from Alpha Cognition’s earnings call?

What is the revenue and EPS growth rate for Alpha Cognition year over year?

What is Alpha Cognition's latest dividend and current dividend yield?

What were the key takeaways from Alpha Cognition's earnings call?

What is the market's earnings forecast for Alpha Cognition next quarter?

- **Revenue Growth**: Q4 net product revenue $2.5M, FY2025 total $10.2M, driven by ZUNVEYL adoption in long-term care.
- **Payer Expansion**: Two major PBMs contracted, with downstream plan implementation expected Q2-Q3 2026.
- **Clinical Momentum**: Three studies (BEACON, CONVERGE, RESOLVE) to validate ZUNVEYL's behavioral benefits and tolerability.
- **Financial Health**: $66M cash, supporting 2026 initiatives and 2027 profitability goal.
- **Innovation**: Sublingual formulation PK study in Q2, targeting dysphagia patients in long-term care.

**【Management Opening Remarks】**
- Interim CFO Henry Du provided forward-looking statements, emphasizing the company's commercial progress and financial results while cautioning on unaudited figures.

**【CEO Commentary】**
- CEO Michael McFadden highlighted ZUNVEYL's successful launch, Q4 net product revenues of $2.5M, and 69% growth in unique facilities with prescriptions.
- Progress includes two national PBM contracts, three clinical studies (BEACON, CONVERGE, RESOLVE), and a 2027 operational profitability target.
- Q4 dispensed bottles reached 4,941, with 1,859 in December, and 82% repeat ordering homes.

**【CFO Financial Commentary】**
- Q4 2025 total revenue: $2.8M (ZUNVEYL: $2.5M, licensing: $0.26M); FY2025: $10.2M (ZUNVEYL: $6.8M).
- Operating expenses: $10.7M (Q4) and $32.9M (FY2025), driven by commercial expansion.
- Net loss: $6.9M (Q4) and $20.7M (FY2025); cash balance: $66M, supporting 2026 initiatives.

**【COO Commercial Update】**
- Q4 demand growth: 600+ repeat prescribers, 729 new homes, and 100 new ordering homes in December.
- Behavioral differentiation and tolerability drove adoption, with 86% prescribers titrating to 10mg.
- Payer pull-through expected in Q2-Q3 2026, with peer-to-peer education activation in Q1.

**【Q&A Highlights】**
- **Payer Progress**: Two major PBMs contracted; downstream plan implementation in Q2-Q3 2026.
- **Clinical Studies**: CONVERGE to assess polypharmacy reduction; BEACON for tolerability and efficacy data.
- **Sublingual Formulation**: PK study in Q2, potential clinic entry in Q1 2027 under 505(b)(2) pathway.
- **Sales Team**: Fully expanded with 98% fill rate, focusing on psychiatry and reimbursement support.

Alpha Cognition Inc (ACOG) Q4 2025 Earnings Call Transcript

- **Revenue growth accelerates**: Q3 ZUNVEYL sales up 44% in ex-factory purchases, 102% in dispensed bottles, driven by 70% reorder rate in nursing homes.
- **Clinical success**: 50% of prescriptions at 10mg dose, with GI adverse events in single digits, exceeding tolerability expectations.
- **Financial strength**: $35.4 million cash + $38 million raise provides 2027 runway; 2025 OpEx guided to $28-30 million with cost discipline.
- **Strategic momentum**: 2 PBM contracts in process, CONVERGE/BEACON studies launching Q4 2025, and CMS Pharma China filing accepted.
- **Pricing resilience**: $820/month WACC adjustment with no pushback, GTN discounts stable at mid-20%.


**【CEO Summary Section】**
- ZUNVEYL achieved strong commercial momentum in Q3 2025, with 1,850 prescribers contacted and 500 nursing homes writing prescriptions. 70% of these homes reordered, indicating product trial success.
- Clinical performance shows low GI adverse events (single digits) and effective titration to 10mg dose in 50% of cases, surpassing expectations for tolerability.
- The company raised $38 million to accelerate growth in behavioral symptom management, with plans for CONVERGE and BEACON studies in long-term care settings.
- CMS Pharma filed for ZUNVEYL approval in China, with potential 2026 approvals in smaller Asian markets.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $2.8 million (ZUNVEYL: $2.3 million, licensing: $0.5 million), up 44% in ex-factory purchases and 102% in dispensed bottles.
- Operating expenses: $8.2 million (vs. $2.5 million in Q3 2024), driven by commercial launch costs. Net loss: $1.3 million (-42% YoY) due to non-cash gains.
- Cash balance: $35.4 million + $38 million raise, providing runway into 2027.
- 2025 OpEx guidance: $28-30 million, reflecting cost discipline (e.g., contract renegotiations, outsourcing).

**【COO Commercial Progress】**
- 2,038 homes engaged (total 2,942), with 605 homes ordering (70% repeat, 15% new in Q3). 576 prescribers wrote orders (62% multiple orders).
- 50-50 split between 5mg and 10mg prescriptions,优于预期的耐受性.
- Payer access: 15% of business under contract with no restrictions; second PBM contract expected by end-2025.
- WACC adjustment to $820.15/month, with GTN discounts in mid-20% range and steady-state net price $500-550.

**【Q&A Highlights】**
- **Payer contracting**: 1 of 4 key PBMs under contract; second expected by end-2025. 15% of downstream plans cover ZUNVEYL without restrictions.
- **Prescriber dynamics**: 62% of Q3 prescribers wrote multiple orders. Providers titrate faster than expected due to low AEs.
- **Pricing impact**: No pushback on $820/month price; GTN discounts remain favorable.
- **China timeline**: Mainland approval likely 2027, with smaller Asian approvals in 2026.


Alpha Cognition Inc. (ACOG) Q3 2025 Earnings Call Transcript

- **ZUNVEYL Commercial Momentum**: 300 nursing homes prescribing, 65% repeat orders, 370 HCPs writing prescriptions.
- **R&D Progress**: Sublingual formulation IND submission in H1 2026; TBI study shows neuroinflammation reduction.
- **Financial Snapshot**: $1.7M Q2 revenue, $10.5M net loss, $39.4M cash balance.
- **Growth Outlook**: Gross to net $575-$625/month; CMS $3M payment Q4 2025; stable 2026 expenses.

**【CEO Summary Section】**
- Successful commercial launch of ZUNVEYL with 3,700 HCP contacts and 300 nursing homes prescribing the drug.
- 65% of nursing homes placed repeat orders, indicating strong product trial.
- Sublingual formulation targeting 20% of Alzheimer's patients with dysphasia/aphasia expected to submit IND in H1 2026.
- CMS partner in China files ZUNVEYL for review, with ex-U.S. revenues anticipated in late 2026.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $1.7M (ZUNVEYL: $1.6M, licensing: $81K).
- Operating loss: $5.7M; net loss: $10.5M ($0.65/share), driven by $5.2M non-cash warrant liability loss.
- Cash balance: $39.4M; 2025 operating expense guidance: $34M-$38M.

**【COO Commercial Update】**
- 1,564 prescribers engaged; 370 HCPs wrote prescriptions (56% wrote >1 order).
- 90% of orders filled despite prior authorization delays.
- Signed contract with a large national PBM (17M Medicare Part D lives); additional contracts in pipeline.

**【Q&A Highlights】**
- Repeat prescribers: focused on high-volume nursing homes with Alzheimer's patients.
- Gross to net: $575-$625/month; CMS $3M tranche expected Q4 2025.
- R&D within expense guidance; no immediate hockey stick from ex-U.S. sales.
- 2026 operating expenses to stabilize at $34M-$38M range.

Alpha Cognition Inc. (ACOG) Q2 2025 Earnings Call Transcript

- **ZUNVEYL Launch Triumph**: Generated $1M in Q1 sales, with 500 bottles ordered and 66% of top LTC targets engaged. Positive clinical feedback highlights reduced agitation and improved sleep.
- **Ex-U.S. Expansion Momentum**: CMS deal for China/Asia territories with Q4 2025 regulatory submissions; another deal expected in late 2025 for 2026 revenue.
- **Financial Resilience**: $45.5M cash, debt-free balance sheet, and reduced Q1 operating loss to $3.7M. Guidance for $38M-$42M 2025 expenses reflects disciplined spending.
- **Payer Access Ease**: Minimal prior authorization requirements, with 50% of Medicare plans allowing simple check-box approvals, enabling rapid adoption without contracts.

**【Management Opening Remarks】**
- Interim CFO Henry Du provided an overview of the Q1 2025 financial results and reminded listeners of the company's forward-looking statements and associated risks.

**【CEO Commentary】**
- **ZUNVEYL Launch Success**: CEO Michael McFadden highlighted the commercial launch of ZUNVEYL, noting $347,000 in Q1 revenue and positive qualitative feedback from prescribers. The drug is now reimbursable by Medicare, a critical milestone.
- **Ex-U.S. Expansion**: Signed a deal with CMS Pharmaceuticals for China and Asian territories, with regulatory submissions expected in Q4 2025. Anticipates modest royalty revenue in 2026 and another deal in late 2025.
- **Patent Strength**: Received U.S. patent approval for a pH-dependent release tablet, extending patent protection to 2044. FDA approval for a method-of-use patent extension is pending.

**【CFO Financial Commentary】**
- **Q1 Financials**: Operating loss decreased to $3.7M (vs. $4.4M in Q1 2024), driven by ZUNVEYL revenue and licensing income. Net loss was $2M, down from $5M in Q1 2024, due to interest income and derivative liability changes.
- **Balance Sheet**: $45.5M in unrestricted cash, debt-free, with sufficient liquidity for ZUNVEYL's long-term care launch.
- **Guidance**: Reiterated 2025 expense range of $38M-$42M, reflecting investments in commercial operations.

**【COO Commercial Update】**
- **Launch Metrics**: 500 bottles ordered in 5 weeks post-Medicare approval, 100 unique accounts with half reordering, and $1M in net sales through April. 66% of top-tier LTC targets engaged, 1,400 homes reached.
- **Payer Access**: Minimal prior authorization requirements, with 50% of plans allowing simple check-box approvals. No significant restrictions despite lack of contracts.
- **Clinical Feedback**: Positive patient outcomes, including reduced agitation and improved sleep, with no reported GI adverse events.

**【Q&A Highlights】**
- **Repeat Prescribers**: Over half of accounts reordered, with repeat writers emerging within weeks.
- **Therapy Duration**: Patients on ZUNVEYL for 1-6 weeks show sustained benefit, with no reports of GI adverse events.
- **Contracting Strategy**: Focused on Medicare in 2025, with plans to expand to commercial in 2026. Early utilization trends will guide formulary decisions.
- **Promotional Channels**: Digital/webinar engagement, medical team outreach, and long-term care conferences driving adoption without sampling.
- **Financial Confidence**: CFO Henry Du confirmed sufficient cash to achieve positive cash flow by year three, with no immediate need for additional funding.

Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript

- **ZUNVEYL Launch Success**: $52M capital raise positions company for breakeven by year three, with commercial manufacturing complete and CMS coverage effective April 2025.
- **Strong Financial Position**: $48.6M cash on hand, operating expenses guided to $38M-$42M, no near-term capital needs for core LTC strategy.
- **Pipeline Differentiation**: Sublingual formulation for 20% of Alzheimer's patients with dysphagia expected Q4 2025, IP protection extended to 2044.
- **Market Momentum**: Overwhelming physician interest in ZUNVEYL's GI benefits, with 140+ years of sales experience team driving early demand.
- **Ex-US Growth**: CMS China partnership underway, exploring second international deal in Europe/Latin America.

**【CEO Summary Section】**
- **Commercial Milestone Achievement**: Successful launch of ZUNVEYL in Q1 2025 with $52M capital raise, enabling breakeven by year three of launch.
- **Manufacturing Progress**: Initiated commercial batches for all ZUNVEYL strengths, with CMC stability tests extending API life to five years.
- **Pipeline Expansion**: Reclaimed two programs (cognitive impairment/TBI, acute pancreatitis) and sublingual formulation development for 20% of Alzheimer's patients with dysphagia.
- **IP Strength**: Secured US patent extending ZUNVEYL protection to 2044, with global approvals expected within 18-24 months.
- **Ex-US Strategy**: CMS partnership for China and Greater Asia, with first territory launches in H2 2025.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: Operating loss of $2.5M (5% YoY increase), net loss of $5.7M ($0.51/share), driven by US equity offering costs.
- **Year-End Cash Position**: $48.6M (vs. $1.4M in 2023), sufficient for long-term care commercialization.
- **2025 Guidance**: Operating expenses $38M-$42M, with no revenue guidance but focus on financial discipline.

**【COO Commercial Progress】**
- **Team Execution**: Hired 140+ years of CNS/LTC experience sales force, completing meetings with top payers and submitting 2026 Medicare bids.
- **Market Access**: CMS coverage effective April 1 with prior authorization, targeting 75%+ long-term care market share.
- **Pricing Strategy**: Wholesale price of $749/month, competitive with branded Alzheimer's therapies.
- **Early Feedback**: Overwhelming physician interest in ZUNVEYL's differentiated GI absorption profile and insomnia benefits.

**【Q&A Highlights】**
- **Coverage Timeline**: First commercial agreements expected Q1 2026, with CMS coverage effective April 2025.
- **Cash Runway**: Current $48.6M cash position sufficient for long-term care launch, with potential additional capital needs for neurology expansion.
- **Pipeline Development**: Sublingual formulation completion Q4 2025, bomb blast trauma study results Q3 2025.
- **Ex-US Expansion**: Exploring second partnership in Europe or Latin America, with CMS leading China efforts.

Actual	-0.51	-0.13	-0.65	-0.08	-0.27
Forecast	-0.63	-0.58	-0.46	-0.43	-0.27
Surprise	+19.05%	+77.59%	-41.30%	+81.40%	0.00%

Actual	0	2.91M	1.68M	2.80M	3.20M
Forecast	0	500.00K	1.66M	2.03M	3.20M
Surprise	0.00%	+482.90%	+1.33%	+37.76%	0.00%

ACOG

ACOG fundamentals

ACOG Q4 2025 Earnings

Earnings Call

You can ask Aime

ACOG

ACOG fundamentals

ACOG Q4 2025 Earnings

Earnings Call

ACOG Earnings Call Summary for Q4/20254:30 PM on Mar 26, 2026

ACOG Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

ACOG Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

ACOG Earnings Call Summary for Q1/20254:30 PM on May 15, 2025

ACOG Earnings Call Summary for Q4/20244:30 PM on Mar 31, 2025

You can ask Aime